Kiora Pharmaceuticals Inc
7EY
Company Profile
Business description
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Contact
332 Encinitas Boulevard
Suite 102
EncinitasCA92024
USAT: +1 858 224-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
12
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,771.10 | 3.90 | -0.04% |
| CAC 40 | 7,742.24 | 57.56 | 0.75% |
| DAX 40 | 23,699.12 | 182.89 | 0.78% |
| Dow JONES (US) | 42,515.09 | 317.30 | 0.75% |
| FTSE 100 | 8,875.22 | 24.59 | 0.28% |
| HKSE | 24,007.22 | 53.77 | -0.22% |
| NASDAQ | 19,701.21 | 294.39 | 1.52% |
| Nikkei 225 | 38,522.20 | 210.87 | 0.55% |
| NZX 50 Index | 12,679.22 | 10.91 | -0.09% |
| S&P 500 | 6,033.11 | 56.14 | 0.94% |
| S&P/ASX 200 | 8,539.60 | 8.80 | -0.10% |
| SSE Composite Index | 3,382.14 | 6.59 | -0.19% |